This analysis evaluates Pfizer's drug portfolio for suitability with Ada Patient Finder, focusing on drugs with significant undiagnosed patient populations, high diagnostic delay, and symptom-based identification potential.
| Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (5% capture) |
|---|---|---|---|---|
| Vyndaqel/Vyndamax (tafamidis) | 1 | 10/10 | 1,163 patients | $3.04M/year |
| Nurtec ODT (rimegepant) | 2 | 9/10 | 2.19 million patients | $476M/year |
| HYMPAVZI (marstacimab) | 2 | 7/10 | 4,000 patients | $6.75M/year |
| LITFULO (ritlecitinib) | 2-3 | 5/10 | 13,400 patients | $3.36M/year |
| ELREXFIO (elranatamab) | NO | 2/10 | N/A | N/A |
| Cibinqo (abrocitinib) | NO | 3/10 | N/A | N/A |
| Talzenna (talazoparib) | NO | 3/10 | N/A | N/A |
| Lorbrena (lorlatinib) | NO | 3/10 | N/A | N/A |
| Ibrance (palbociclib) | NO | 2/10 | N/A | N/A |
| Xtandi (enzalutamide) | NO | 2/10 | N/A | N/A |
| Bosulif (bosutinib) | NO | 2/10 | N/A | N/A |
| Xeljanz (tofacitinib) | NO | 2/10 | N/A | N/A |
| Braftovi/Mektovi | NO | 3/10 | N/A | N/A |
| Zavzpret (zavegepant) | NO | 4/10 | N/A | N/A |
| Oxbryta (voxelotor) | NO | N/A | N/A | Withdrawn from market |
| Indication | Transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) |
| Addressable Undiagnosed (USA) | 1,163 patients |
| Addressable Undiagnosed (DACH) | 818 patients |
| Addressable Undiagnosed (ROW) | 2,500 patients |
| Total Global Addressable | 4,481 patients |
| Revenue per Patient (USA) | $170,000/year |
| Patient Finder Fee (USA) | $17,000 per patient |
| Annual Revenue (2024) | $5.45 billion (+65% YoY) |
| Peak Revenue Forecast | $17-19 billion by 2031-2032 |
| Patent Expiry (US) | 2035 (Vyndamax) |
| Capture Rate | Patients Found | Ada Revenue/Year |
|---|---|---|
| 1% | 45 patients | $608,100 |
| 5% | 224 patients | $3.04 million |
| 10% | 448 patients | $6.08 million |
| Indication | Migraine (acute treatment and preventive) |
| Addressable Undiagnosed (USA) | 2.19 million patients |
| Addressable Undiagnosed (DACH) | 670,000 patients |
| Addressable Undiagnosed (ROW) | 5 million patients |
| Total Global Addressable | 7.86 million patients |
| Revenue per Patient (USA) | $17,000/year (blended acute + preventive) |
| Patient Finder Fee (USA) | $1,700 per patient |
| Annual Revenue (2022) | $721.3 million (pre-Pfizer acquisition) |
| Peak Revenue Forecast | $2 billion by 2029 |
| Patent Expiry (US) | 2030 |
| Capture Rate | Patients Found | Ada Revenue/Year |
|---|---|---|
| 1% | 78,600 patients | $95.4 million |
| 5% | 393,000 patients | $476 million |
| 10% | 786,000 patients | $952 million |
Note: This is the LARGEST ABSOLUTE REVENUE OPPORTUNITY in Pfizer's portfolio due to massive underdiagnosis (7.86M globally).
| Indication | Hemophilia A/B (without inhibitors, age 12+) |
| Addressable Undiagnosed (USA) | 4,000 patients |
| Addressable Undiagnosed (DACH) | 500 patients |
| Addressable Undiagnosed (ROW) | 4,000 patients |
| Total Global Addressable | 8,500 patients |
| Revenue per Patient (USA) | $200,000/year (estimated) |
| Patient Finder Fee (USA) | $20,000 per patient |
| Launch Status | PDUFA Q2 2026 (without inhibitors indication) |
| Market Size | Hemophilia market: $21.24B by 2032 |
| Capture Rate | Patients Found | Ada Revenue/Year |
|---|---|---|
| 1% | 85 patients | $1.35 million |
| 5% | 425 patients | $6.75 million |
| 10% | 850 patients | $13.5 million |
| Indication | Severe alopecia areata (SALT ≥50, age 12+) |
| Addressable Undiagnosed (USA) | 13,400 patients |
| Addressable Undiagnosed (DACH) | 1,500 patients |
| Addressable Undiagnosed (ROW) | 75,000 patients |
| Total Global Addressable | 89,900 patients |
| Revenue per Patient (USA) | $10,000/year |
| Patient Finder Fee (USA) | $1,000 per patient |
| Launch Date | June 2023 (early post-launch) |
| Market Size | Alopecia areata market: $379M (2023) |
| Capture Rate | Patients Found | Ada Revenue/Year |
|---|---|---|
| 1% | 899 patients | $671,000 |
| 5% | 4,495 patients | $3.36 million |
| 10% | 8,990 patients | $6.71 million |
| Drug | Indication | Rejection Reason |
|---|---|---|
| ELREXFIO (elranatamab) | Multiple myeloma (late-line) | Small eligible population (~74 patients annually), not a diagnostic gap, heavily pretreated patients |
| Cibinqo (abrocitinib) | Atopic dermatitis | Visible skin condition, diagnosed early (childhood), no diagnostic delay, treatment navigation not diagnosis gap |
| Talzenna (talazoparib) | BRCA+ breast cancer | Genetic testing gap (not symptom-based), Ada cannot identify BRCA mutations through symptoms, small market (5-10% of breast cancers) |
| Lorbrena (lorlatinib) | ALK+ NSCLC | Molecular testing gap (requires FISH/NGS), not symptom-based, small market (3-5% of NSCLC) |
| Ibrance (palbociclib) | HR+/HER2- breast cancer | Mass market (70% of breast cancers), well-screened, declining revenue (-8.4% YoY), patent expiry approaching |
| Xtandi (enzalutamide) | Prostate cancer | Well-screened condition (PSA), 70% diagnosed at localized stage, partnership drug (Astellas), no diagnostic gap |
| Bosulif (bosutinib) | Chronic myeloid leukemia | Lab-based diagnosis (blood tests, BCR-ABL), not symptom-identifiable, small revenue ($575M) |
| Xeljanz (tofacitinib) | RA, UC, PsA | Patent cliff (Aug 2028), black box warnings, declining revenue, visible conditions |
| Braftovi/Mektovi | BRAF+ cancers | Molecular testing gap (BRAF V600E requires IHC/NGS), not symptom-based, small subset (10% of CRC) |
| Zavzpret (zavegepant) | Migraine (acute) | Lower priority than Nurtec ODT (same indication), newer launch, acute-only vs. Nurtec's dual indication |
| Oxbryta (voxelotor) | Sickle cell disease | WITHDRAWN from all markets (Sept 25, 2024) due to safety concerns (vaso-occlusive crises, deaths) |
Why pursue aggressively:
Single biggest strategic fit in Pfizer portfolio for Patient Finder.
Why pursue:
Challenges:
BUT: The sheer scale ($476M Ada revenue at 5% capture) makes this highly attractive. Biggest absolute revenue opportunity in Pfizer portfolio.